Home > Expanded Access > Individual Patient Compassionate Use of Triheptanoin

Ultragenyx Pharmaceutical Inc

Individual Patient Compassionate Use of Triheptanoin

Brief Summary: 
Individual patient expanded access requests may be considered for patients who have no other treatment options
Detailed Description: 

Expanded access may provide access for treatment prior to approval by the local regulatory agency. For full details, please visit the link provided.

EA Type
Individual Patients
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Drug: Triheptanoin
Other Name: UX007

Eligibility Criteria: 

Inclusion Criteria:


Exclusion Criteria:


Eligibility Gender: 

Early Access

Ultragenyx Pharmaceutical Inc
EA Number: 
Expanded Access, Compassionate Use
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.